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Background: Overdose is a major cause of death amongst PWID, and for opioid overdoses 
naloxone administration can reduce harm. However, globally there is limited national level 
data on the extent of non-fatal overdose and naloxone uptake. The first national level data 
on the extent of self-reported overdose and self-reported receipt of naloxone among UK 
PWID, providing a baseline to monitor the impact of the recent policy change regarding 
naloxone availability, is presented. 
 
Methods: Data on self-reported overdose and receipt of naloxone during the preceding year 
for 2013-2014 from a national survey of PWID was analysed.  Participants who reported 
injecting during the preceding year were included. 
 
Results: Participants (3,850) were predominantly male (75%); mean age was 36 years. The 
most commonly injected drugs were: heroin (91%), crack (45%) and amphetamine (29%). 
15% (591) reported overdosing during the preceding year. There were no differences in the 
proportion reporting overdose by age or gender, but overdose was more common among 
those who: injected multiple drugs; recently ceased addiction treatment; injected with used 
needles/syringes; ever had transactional sex; had used a sexual health clinic or emergency 
department and lived in Wales or Northern Ireland. Among those reporting an overdose 
during the preceding year, a third reported two to four overdoses and 7.5% five or more 
overdoses; half reported receiving naloxone.  Those reporting naloxone receipt in the 
preceding year were more likely to: live in Wales or Northern Ireland; ever received used 
needles/syringes; ever been imprisoned; and less likely to have injected two drug types. 
 
Conclusions: These data provide a baseline for monitoring the impact of the 2015 UK policy 
change to improve take-home naloxone access. Interventions tackling overdose should 
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promote naloxone awareness and access, and target those who; are poly-drug injectors, 
have ceased treatment, share needles/syringes and whose drug use links to sexual activity. 
 
 
 
Introduction  
 
Overdose is a major cause of mortality among people who inject drugs (PWID), 
especially in those who inject opioids such as heroin (Pierce, Bird, Hickman, & 
Millar, 2015; Strang, 2015). The United Nations World Drug Report 2015 described 
the number of these premature deaths in drug users as “unacceptable” (United 
Nations Office on Drugs and Crime, 2015) because the majority are preventable 
through interventions such as long-term opioid substitution therapy and the use of 
opioid antagonists, such as naloxone. 
 
In 2015, drug-induced overdose was the leading cause of injury-related death in the 
United States (US) (Hedegaard, Chen, & Warner, 2015), with the rate of fatal drug 
overdoses involving opioids doubling between 2000 to 2014 (Rudd, Aleshire, 
Zibbell, & Gladden, 2016) and the heroin overdose mortality rate nearly tripling 
between 2010 and 2013 (Hedegaard, et al., 2015). Reported overdose deaths have 
also been increasing in other countries such as Australia (Roxburgh & Burns, 2015), 
and Canada. In Ontario, Canada, drug related overdose is the third leading cause of 
accidental death (Carter & Graham, 2013) with the rate of opioid-related deaths 
doubling between 1991 and 2010 (Gomes, et al., 2014). The European Drug Report 
estimated that 3.4% of all deaths in Europeans aged 15-39 were due to drug 
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overdoses in 2013, and opioids were found in 82% of fatal overdoses in Europe in 
2014 (European Monitoring Centre for Drugs and Drug Addiction, 2015, 2016).  
 
In 2015, there were 3,288 registered drug-misuse deaths in the UK, with 81% 
(n=2,677) of these deaths mentioning an opioid.   In recent years there been a 
marked increases in the number of drug-misuse deaths were an opioid is mentioned 
across the UK  (with increases of 58% in England, 21% in Scotland,  23% in Wales 
and 47% in Northern Ireland  between 2012 and 2015) (Advisory Council on the 
Misuse of Drugs, 2016). A national inquiry to investigate the causes of this rise 
concluded that the factors responsible  were principally the availability and purity of 
heroin (Public Health England, 2016) 
 
Naloxone is a powerful, yet relatively safe opioid-antagonist that temporarily blocks opioid 
receptors, thus reversing respiratory depression, sedation and hypotension caused by 
excess opioid ingestion (Hospira Inc., 2007; Strang & McDonald, 2016b).  
 
In 2014 the World Health Organization (WHO) recommended that people likely to witness 
overdose (such as friends and family of people who use drugs, healthcare workers and 
police) should have access to naloxone and be trained in its administration (World Health 
Organization, 2014). A recent review of evaluations of Take-Home Naloxone (THN) 
programmes in the US, Canada, Germany and the UK, found that these significantly 
reduced heroin overdose mortality rates (Strang & McDonald, 2016a) . As of September 
2015, 43 US states had legalised naloxone access for peers (Davis & Carr, 2015), as well 
as New York state developing an opioid-overdose prevention and training program 
targeting all soon to be released inmates and parole officers (Zucker, Annucci, Stancliff, & 
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Catania, 2015). Australia has recently become the second country (after Italy in 1995) to 
approve naloxone as an over-the-counter (OTC) drug (Australian Government Department 
of Health, 2015; Lenton, Dietze, & Jauncey, 2016; Strang & McDonald, 2016b) and a 
number of US states have also proposed this (Beheshti, et al., 2015; Kim, Irwin, & 
Khoshnood, 2009).  
 
In Scotland, as part of  a National Naloxone Programme, THN kits have been provided to 
those at risk of overdose through Patient Group Direction (PGD) (Watt, et al., 2014) and 
this was associated with a 36% reduction in opioid-related deaths following prison release 
(Bird, McAuley, Perry, & Hunter, 2016), although recently there has been evidence to 
suggest a decline in day-to-day naloxone carriage among PWID in Scotland (McAuley, et 
al., 2016). In Wales, a national THN programme has issued over 10,500 THN kits since it 
was initiated in 2009, with one in ten reported to have been used in overdose events (Public 
Health Wales, 2016). In Northern Ireland, a THN programme has been available via drug 
treatment services from community addiction teams since 2012. Work is currently ongoing 
to extend the provision of naloxone to other services, for example community outreach 
teams (personal communication, L Jessop 2016). 
 
In October 2015, UK regulations changed to allow naloxone to be supplied by drug 
treatment services (including prison and pharmacy based services) without a prescription. 
Previously it could only be prescribed either directly to a named patient or through a PGD. 
The supply of naloxone is not limited specifically to PWID at risk of overdose, and it can 
now be supplied to peers, friends and family of those at risk as well as people such as 
outreach workers (Public Health England, 2015b).  
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In the UK, there is currently limited national data on the extent of recent self-reported 
overdose and receipt of naloxone among PWID. To assess the impact of the recent change 
in legislation, national baseline data on the extent of overdoses and receipt of naloxone is 
needed. Using new data from a national survey of PWID in the UK (excluding Scotland) we: 
a) examine the extent of reported overdoses nationally among PWID, b) explore the factors 
associated with this, and c) examine the extent of naloxone uptake among those who had 
reported overdose.
Material and Methods 
 
Recruitment and data  
PWID at sentinel locations have been recruited into a voluntary unlinked-anonymous 
monitoring system since 1990.  Methodological details of this system, a series of annual 
cross-sectional surveys, have been published previously (Hope, et al., 2005; Sweeting, et 
al., 2009).  Briefly, agencies providing services to PWID (e.g. needle and syringe 
programmes [NSPs] and providers of addiction services such as opioid substitution therapy 
[OST]) invite clients who have ever injected a psychoactive drug to participate in the survey 
each year. These sentinel sites are located throughout the UK, except Scotland, and are 
selected so as to reflect both the geographic distribution and range of services offered to 
PWID. Those who consent to participate provide a biological sample, currently a dried 
blood spot (DBS), and self-complete a short questionnaire. The DBS samples are tested for 
antibodies to HIV (anti-HIV), hepatitis C (anti-HCV) and the hepatitis B core anti-gen (anti-
HBc) using published methods. The survey has received multi-site ethics approval.    
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In 2013, a question on self-reported overdoses and naloxone use was added to the survey 
questionnaire. Participants were asked: “In the last year (12 months), have you ever 
overdosed (OD-ed, gone over, gone-under) to the point where you have lost 
consciousness?” Those reporting ‘yes’ were then asked how many times they had 
overdosed in the preceding year, as well as, “In the last 12 months, did you receive 
naloxone (the heroin overdose antidote) when you overdosed?”. 
 
Eligibility & analysis 
Data from the first participations in the two survey waves undertaken during 2013 and 2014 
were used in the analyses (i.e. those taking part in 2014 who reported having previously 
taken part in 2013 were excluded). Participants were included in the analyses if they 
reported injecting in the preceding year and answered the question on overdose.  
 
Simple descriptive analyses and comparative analyses, using Pearson’s Chi-squared test 
were performed to assess the bivariate association between the two outcome variables 
(overdosing to the point of unconsciousness in the preceding year and receiving naloxone 
in the preceding year when overdosed), and covariates (demographics, injecting practices, 
the drugs injected, sexual behaviour, and health services use). Where possible 
associations were found (p<0.10) with either of the outcomes, these were then further 
examined via binary logistic regression using the forward stepwise procedure to select 
variables for inclusion in the model, with selection based on the likelihood ratio test 
(p<0.05). All analyses were undertaken using SPSS 23.
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Results 
 
Sample characteristics  
During 2013 and 2014, there were 3,850 participants in the survey who reported injecting 
psychoactive drugs during the preceding year. Over half (56%, n=2,139) were aged 35 
years or older (mean and median age both 36 years), the majority 75% (n=2,893) were 
male, and 6.4% (n=248) had been born outside of the UK. The most commonly injected 
drug in the past year was heroin (91%, n=3,508) followed by crack (45%, n=1,719), 
amphetamine (29%, n=1,096), cocaine (13%, n=499), mephedrone (8.2%, n=316), 
methadone (4.8%, n=186) and ketamine (4.8%, n=183). Almost one in 10 reported that 
they injected another drug (i.e. one that had not been specifically asked about, 9.0%, 
n=345); 38% reported injecting only one drug type, 37% reported injecting two drug types, 
14% three drug types and 11% four or more drug types. 
Proportion reporting overdose  
Overall, 15% (n=591) reported that they had overdosed to the point of unconsciousness in 
the preceding year. Of those who reported overdosing, 55% (n=323) reported overdosing 
only once in the preceding year, 34% (n=198) reported overdosing two to four times and 
7.5% (n=44) reported overdosing five or more times (for 4.4% [n=26] frequency of overdose 
was not reported). 
Factors associated with self-reported overdose 
The factors associated with having overdosed in the bivariate and multivariable analyses 
are shown in Table 1. In the multivariable analysis, self-reported overdose during the 
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preceding year was associated with injecting heroin and polydrug injection, (being most 
common) among those who had injected four or more drug types.  Self-reported overdose 
was also more common among those who reported: previously being prescribed a detox or 
maintenance drug (compared to those who had never or were currently being prescribed); 
injecting with previously used works (needles/syringes); ever having transactional sex; 
using a sexual health clinic in the last 12 months; and using an emergency department in 
the last 12 months. Reporting overdose in the past year was also more common among 
those living in Wales and Northern Ireland, compared to those living in England.  
[INSERT TABLE 1 NEAR HERE] 
Survey participants were asked about oral use of selected drugs during the preceding 
month.  Overall, 29% (1,118/3,850) reported that they had swallowed non-prescribed 
benzodiazepines.  Oral use of benzodiazepines in the preceding month was more common 
among those reporting an overdose during the preceding year (p<0.0001, 40% [237/591] of 
those who reported an overdose had swallowed benzodiazepines, compared to 27% 
[881/3,259] of those not reporting an overdose). 
 
Extent of, and factors associated with, self-reported receipt of naloxone  
Of the 591 participants reporting overdose in the past year, 477 were able to report whether 
they had received naloxone or not. Just under half (45%, 213/477) reported that they had 
received naloxone when they overdosed (the remaining 114 of those who had overdosed 
were not sure or didn’t know if they had received naloxone). 
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The factors associated with self-reported receipt of naloxone in the bivariate and 
multivariable analyses are presented in Table 2. In the multivariable analysis, receiving 
naloxone after overdosing was, as expected, more common among those who had injected 
heroin in the past year. Self-reported receipt of naloxone was also more common in those 
who reported: ever receiving previously used works (needles/syringes) from someone else; 
and ever being imprisoned. Self-reported receipt of naloxone was also more common in 
those living in Wales and Northern Ireland, compared to those living in England. Uptake 
was less common among those injecting two drug types, compared to those injecting only 
one type. 
[INSERT TABLE 2 NEAR HERE]
Discussion 
 
Overview of Findings 
This is the first analyses to use national level data on overdose and naloxone use among 
PWID across England, Wales and Northern Ireland. Our data suggests that one in seven 
PWID report overdosing to the point of unconsciousness annually.  One-third of these had 
reported an overdose on between two and four occasions, and one in 12 reported five or 
more overdoses during the preceding year. Previously, there has been limited national level 
data on the extent of non-fatal overdose among PWID, although studies suggest overdose 
is common and can be frequent, with some indicating frequencies of one to two overdoses 
a year (Bazazi, et al., 2015; Darke, et al., 2007; Grau, et al., 2009; Holloway, Bennett, & 
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Hills, 2016; Wagner, et al., 2015). Just under half of those who reported overdose reported 
that they had received naloxone, though many were unsure. 
 
 
Factors associated with self-reported overdose 
Self-reported overdose was two and a half times more common in those who reported 
injecting heroin in the past year compared to those who hadn’t. This increased frequency of 
overdose in heroin injectors is most likely due to the physiological effects heroin has and 
the nature of a heroin overdose; there is often a fine line between acute respiratory 
suppression and when heroin dosage becomes toxic causing respiratory failure, hypoxia 
and potentially death (Jolley, Bell, Rafferty, Moxham, & Strang, 2015; White & Irvine, 1999). 
Batches of street heroin that have been linked to overdose risk have also been documented 
as being more popular among some groups of PWID due to the ‘better’ euphoric effects 
(Mars, et al., 2015; Singer, 2006). However, these effects are usually at the brink of 
overdose. Tolerance to respiratory depression in people who inject heroin can develop 
quickly with chronic use, but can be lost quickly in withdrawal, making the judgement of 
lethal doses hard to predict (Mars, et al., 2015; Strang, et al., 2003). Street heroin with 
variable purity levels and price due to the variances of supply, make it harder to identify a 
lethal dosage, particularly after heroin shortages when the ‘normal’ quality resumes (Darke, 
Hall, Weatherburn, & Lind, 1999; Travis, 2011; Unick, Rosenblum, Mars, & Ciccarone, 
2014). 
Self-reported overdose was also more common in those reporting polydrug injection, and 
was nearly two and a half times more common in those injecting four or more drug types 
compared to only one drug type. This finding is in line with other studies that show 
overdose and drug-related deaths are more common among polydrug-using PWID (Darke, 
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2003; Fairbairn, et al., 2008; Hickman, Carrivick, et al., 2007; Kaye & Darke, 2004; 
Petrushevska, Jakovski, Poposka, & Stefanovska, 2015; Powis, et al., 1999; Richer, 
Bertrand, Vandermeerschen, & Roy, 2013; Rossow & Lauritzen, 1999; Webb, et al., 2003). 
Co-use of opioids with other central nervous system depressant drugs such as methadone, 
which is often prescribed for opioid-dependence (Wunsch, Nuzzo, Behonick, Massello, & 
Walsh, 2013), can cause compounded depression of the respiratory system, potentiating 
the detrimental effects on breathing and heightening the risk of overdose (Coffin, et al., 
2003; Ochoa, et al., 2005; Warner-Smith, Darke, Lynskey, & Hall, 2001). Two-thirds of our 
sample reported currently receiving prescribed treatment for their drug use suggesting 
many are or have been injecting on top of their opiate substitution therapy (which is typically 
methadone in the UK). Although our survey does not ask about injection of 
benzodiazepines (a depressant drug) as this is rare in the UK, with data from surveys 
undertaken in England using respondent driven sampling (Hope, Ncube, Parry, & Hickman, 
2015) found only 1.5% reported injecting benzodiazepines during the preceding year 
(personal communication, V Hope 2016), self-reported overdose was also significantly 
more common among those who reported swallowing non-prescribed benzodiazepines in 
the past month. The use of stimulants and opiates at the same time, or 
“Speed/snowballing”, can increase overdose risks, and in the UK heroin and crack-cocaine 
are common drug combination among PWID (Public Health England, 2015a; Turning Point, 
2007). Co-use of heroin and cocaine, commonly used interchangeably compensate for 
depressant or stimulant withdrawal (Guzman & Ettenberg, 2004; Leri, Bruneau, & Stewart, 
2003) may also  cause an individual to be more at risk to opioid overdose (Fiala, et al., 
1998; Zhang, et al., 1998)  and can cause unpredictable respiratory depression if the 
stimulant effects mask the delayed effects of opioid overdose (Cattelle, 2015; Newcombe, 
2007; Treatment4addiction).  
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Currently being prescribed treatment for drug addiction was protective for self-reported 
overdose in our study, as this population was less likely to report overdose compared to 
those who had previously been prescribed treatment. Those who had previously been 
treated for addiction, but who have ceased therapy, have been documented as having a 
high mortality risk, and may represent a group of PWID that are harder to reach and target 
in harm reduction strategies  (Davoli, et al., 1993; Seal, et al., 2001). The link between 
recent release from drug treatment programs and self-reported overdose is most likely due 
to lowered drug tolerance following periods of drug abstinence during detoxification (Strang, 
et al., 2003) or patients lost to follow up, and highlights the need for enhanced aftercare 
once a PWID has completed or prematurely left a drug treatment programme. 
Those who reported injecting with previously used needles and syringes were also more 
likely to have reported overdose in the past year; with a quarter of those who had shared 
needles/syringes also reporting overdosing. This finding might reflect a group of more 
chaotic users with a range of risky injecting practises, but more research is needed. 
Overdose, as would be expected, was commonly reported in those who had recently 
attended an emergency department, but was also more commonly reported among those 
who had attended a sexual health clinic in the preceding year. As the level of self-reported 
overdose was also elevated among those reporting transactional sex, this could indicate a 
vulnerable population in which chaotic or unsafe drug use is linked to increased sexual 
risks, as well as highlighting the opportunity to offer this population interventions in sexual 
healthcare settings. This link needs further exploration to determine how overdose is 
related to sexual activity. 
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Factors associated with self-reported receipt of naloxone  
Receipt of naloxone was reported in just under half of those who reported overdosing and 
injecting heroin during the past year, similar to that reported in previous small-scale studies 
(Holloway, et al., 2016). Since the majority of heroin injectors sampled did not report 
receiving naloxone when they overdosed, this could indicate a substantive need for 
improved provision and accessibility of naloxone. The recent UK legislative change allowing 
wider availability of naloxone could thus have the potential to positively impact on the harm 
from overdose. 
Self-reported receipt of naloxone after overdose was significantly lower among those 
injecting two drug types, compared to those injecting only one drug type, or those injecting 
three drug types. This disparity in naloxone provision could be due to the injection of heroin 
and crack together being common in much of the UK (Hickman, Hope, et al., 2007; Public 
Health England, 2015a). The injection of these two drugs in combination has been 
associated with chaotic behaviour, which might impact on access to naloxone. 
Those who reported ever being imprisoned were also one and a half times more likely to 
have reported receiving naloxone, but those who had ever been imprisoned were not more 
likely to have reported an overdose. This higher level of self-reported naloxone receipt 
among this group could be due to the recent N-ALIVE trial (Strang, Bird, & Parmar, 2013) 
where prisoners in England and Wales were given naloxone on prison release, or that 
PWID who have recently been released from prison are more likely to recognise their 
vulnerability to overdose.  
Those in Wales and Northern Ireland were also twice as likely to report receiving naloxone 
when they overdosed compared to those in England. These variations may reflect varying 
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local approaches in naloxone provision, such as the THN programmes in Wales and 
Northern Ireland. However, this also may be due to a higher level of reported overdose in 
these areas; one in five individuals from Wales and Northern Ireland reported overdosing in 
the past year and they were one and a half times more likely to overdose compared to 
PWID England.  This and the association of reporting ever receiving previously used works 
(needles/syringes) need further investigation. 
 
Limitations 
This study has several limitations. Firstly, the behavioural data used here is based on self-
reports, the accuracy of which may be subject to recall bias. However, previous studies 
have demonstrated the reliability of self-report risk behaviours among people who inject 
drugs (Latkin, Vlahov, & Anthony, 1993). However, due to loss of the consciousness self-
reports of overdose and naloxone receipt may be particularly affected by recall issues. 
Secondly, the illicit and marginalised nature of injecting drug use makes the recruitment of a 
representative sample problematic. To maximise representativeness, this survey used the 
extensive provision of targeted services for people who inject drugs as a sampling frame. In 
the UK, the uptake and use of such targeted services is high, with very few of the people 
who inject drugs recruited through community based studies found not to be in contact with 
such services (Craine et al., 2010; Hickman et al., 2007). 
Finally, it is possible that those who have received naloxone may not always be aware of 
this when they have lost consciousness, and so receipt of naloxone may be under reported. 
Considering these issues, caution should be used when generalising the findings presented 
here. 
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Conclusions 
 
Overdose has been recognised as a major cause of death in PWID, and previous overdose 
is a significant predictor of mortality (Darke, Mills, Ross, & Teesson, 2011). Interventions 
and harm reduction strategies should focus on reducing opioid overdoses in PWID by 
promoting naloxone uptake and targeting those most at risk; notably those who inject 
multiple drugs, those who have recently stopped treatment, and those whose drug use may 
be linked to sexual activity. 
Our analysis presents baseline national data on the extent of self-reported overdose and 
self-reported receipt of naloxone among PWID in the UK from an ongoing survey 
programme.  Data from future survey waves can be used to examine the impact of 
legislative changes allowing wider access to naloxone in the UK that came into effect in 
October 2015. 
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Results Table 1 
Table 1. Factors associated with self-reported overdose in the preceding year among PWID in England, Wales and N.Ireland: 2013-14. 
Variable   Value   Self-reported overdose?*     
  Yes 
15% (591) 
Total 
100% (3,850) 
p - 
value 
Adjusted Odds Ratio, 
with 95% confidence 
interval         % n % n 
Ever been prescribed a detox or 
maintenance drug regime (such as 
opioid substitution therapy)? 
 
Never/Not Reported 
 
15% 93 100% 630 
<0.0001 
1.00 
   
 
Previously prescribed 
 
22% 125 100% 580 1.17 0.85 - 1.61 
 
Currently prescribed 
 
14% 373 100% 2,640 0.72 0.55 - 0.94 
             
Injected heroin?*  
No 
 
7.0% 24 100% 342 
<0.0001 
1.00 
   
 
Yes 
 
16% 567 100% 3,508 2.26 1.43 - 3.56 
             
Injected crack?*  
No 
 
12% 262 100% 2,131 
<0.0001 † 
 
Yes 
 
19% 329 100% 1,719 
             
Injected ketamine?*  
No 
 
15% 542 100% 3,667 
<0.0001 † 
 
Yes 
 
27% 49 100% 183 
             
Injected cocaine?*  
No 
 
14% 468 100% 3,351 
<0.0001 † 
 
Yes 
 
25% 123 100% 499 
             
Injected mephedrone?*  
No 
 
15% 517 100% 3,534 
<0.0001 † 
 
Yes 
 
23% 74 100% 316 
             
Injected other drugs?*  
No 
 
14% 503 100% 3,505 
<0.0001 † 
 
Yes 
 
26% 88 100% 345 
             
Polydrug injection use*‡ 
 
Only 1 drug type/Not 
Reported 
 
10% 142 100% 1,477 
<0.0001 
1.00 
   
 
2 drug types 
 
17% 242 100% 1,419 1.69 1.34 - 2.14 
 
3 drug types 
 
18% 93 100% 530 1.42 1.06 - 1.92 
 
4 or more drug types 
 
27% 114 100% 424 2.31 1.72 - 3.11 
             Had an abscess, sore or open wound 
at an injection site?* 
 
No/Not Reported 
 
14% 398 100% 2,852 
<0.0001 † 
 
Yes 
 
19% 193 100% 998 
             Injected with a needle/syringe that had 
already been used by someone else?* 
 
No/Not Reported 
 
14% 437 100% 3,235 
<0.0001 
1.00 
   
 
Yes 
 
25% 154 100% 615 1.60 1.26 - 2.03 
             Ever received used needles or 
syringes from anyone? 
 
No/Not Reported 
 
13% 254 100% 2,036 
<0.0001 
1.00 
   
 
Yes 
 
19% 337 100% 1,814 1.32 1.08 - 1.61 
             
Had sex (vaginal or anal)?*  
No/Not Reported 
 
13% 158 100% 1,199 
0.012 † 
 
Yes 
 
16% 433 100% 2,651 
             
Ever received money, goods or drugs 
in exchange for sex? 
 
Never/Not Reported 
 
14% 487 100% 3,409 
<0.0001 
1.00 
   
 
Yes but not in last year 
 
18% 42 100% 236 1.07 0.74 - 1.54 
 
Yes, in the last year 
 
30% 62 100% 205 1.94 1.38 - 2.73 
             Used a Sexual Health, GUM or STI 
Clinic?* 
 
No/Not Reported 
 
14% 489 100% 3,449 
<0.0001 
1.00 
   
 
Yes 
 
25% 102 100% 401 1.66 1.27 - 2.16 
             
Used an NHS Walk-In clinic?*  
No/Not Reported 
 
15% 458 100% 3,102 
0.04 † 
 
Yes 
 
18% 133 100% 748 
             
Used an emergency department?*  
No/Not Reported 
 
11% 294 100% 2,676 
<0.0001 
1.00 
   
 
Yes 
 
25% 297 100% 1,174 2.62 2.17 - 3.15 
             Used none of the listed health 
services?* 
 
No/Not Reported 
 
16% 538 100% 3,386 
0.012 † 
 
Yes 
 
11% 53 100% 464 
             
Region 
 
South incl. London 
 
18% 70 100% 399 
0.003 
1.00 
   
 
Midlands & East of 
England 
 
14% 207 100% 1,504 
0.92 0.67 - 1.26 
 
North England 
 
15% 222 100% 1,500 1.04 0.76 - 1.42 
 
Wales & N. Ireland 
 
21% 92 100% 447 1.48 1.02 - 2.13 
There was no association in the bivariate analyses with: ever being in prison/young offenders institution in the last year; whether UK born; using 
a needle/syringe programme in the last year; whether injected speed or methadone in the last year;  ever being vaccinated for hepatitis B; using 
a family planning clinic in the last year; or a GP/family doctor in the last year 
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* in the last year 
† Entered in to the multivariable analysis, but not in final model 
‡ Those injecting 2 or more drug types will include both those co-injecting drugs (i.e. using drug combinations) and those injecting several drugs 
separately 
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Results Table 2 
Table 2. Factors associated with self-reported receipt of naloxone among PWID reporting overdose in the preceding year in England, Wales and N.Ireland: 2013-14. 
Variable 
  
Value 
  
Reported receipt of naloxone when 
overdosed?*   
  
  
  
Yes 
45% (213) 
Total 
100% (477) 
p - 
value 
Adjusted Odds Ratio, with 
95% confidence interval 
  
        % n % n 
  
Injected heroin?*  
No 
 
12% 2 100% 17 
0.005 
1.00 
      Yes 
 
46% 211 100% 460 8.47 1.83 - 39.26 
                 
Injected other drugs?*  
No 
 
43% 169 100% 398 
0.031 † 
   
Yes 
 
56% 44 100% 79 
                 
Polydrug injection use* 
 
Only 1 drug type /Not Reported 
 
47% 52 100% 110 
0.024 
1.00 
      2 drug types 
 
37% 73 100% 197 0.58 0.35 - 0.96 
   
3 drug types 
 
47% 35 100% 74 0.87 0.47 - 1.612 
   
4 or more drug types 
 
55% 53 100% 96 1.20 0.67 - 2.123 
                 
Ever received used needles/syringes from anyone?  
No/Not Reported 
 
39% 78 100% 202 
0.023 
1.00 
      Yes 
 
49% 135 100% 275 1.62 1.10 - 2.38 
                 
Used an emergency department?*  
No/Not Reported 
 
40% 95 100% 237 
0.046 † 
   
Yes 
 
49% 118 100% 240 
                 
Region 
 
South incl. London 
 
40% 25 100% 62 
0.053 
1.00 
      Midlands & East of England 
 
46% 75 100% 165 1.30 0.70 - 2.428 
   
North England 
 
40% 68 100% 172 0.94 0.50 - 1.749 
   
Wales & N. Ireland 
 
58% 45 100% 78 2.04 1.007 - 4.152 
                 
Ever been in prison/young offenders institution?  
No/Not Reported 
 
38% 54 100% 144 
0.039 
1.00 
      Yes 
 
48% 159 100% 333 1.59 1.04 - 2.44 
  
There was no association in the bivariate analyses with: age; whether UK born; using a needle/syringe programme in the last year; being prescribed treatment for drug use; injecting crack, speed, ketamine, 
methadone, mephedrone or cocaine in the last year; having an abscess/sore or open wound at injection site in the last year; injecting with used works; having sex in the last year; ever having transactional 
sex; ever being vaccinated for hepatitis B; using a sexual health/GUM/STI clinic/family planning clinic/NHS walk-in clinic/GP/family doctor or none of these services in the last year. 
  *in the last year 
              † Entered in to the multivariable analysis, but not in final model                 
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